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Abstract
Dendritic cells (DCs) are activated by signaling via pathogen-specific receptors or exposure to inflammatory mediators. Here
we show that co-culturing DCs with apoptotic HIV-infected activated CD4
+ T cells (ApoInf) or apoptotic uninfected activated
CD4
+ T cells (ApoAct) induced expression of co-stimulatory molecules and cytokine release. In addition, we measured a
reduced HIV infection rate in DCs after co-culture with ApoAct. A prerequisite for reduced HIV infection in DCs was
activation of CD4
+ T cells before apoptosis induction. DCs exposed to ApoAct or ApoInf secreted MIP-1a, MIP-1b, MCP-1,
and TNF-a; this effect was retained in the presence of exogenous HIV. The ApoAct-mediated induction of co-stimulatory
CD86 molecules and reduction of HIV infection in DCs were partially abrogated after blocking TNF-a using monoclonal
antibodies. APOBEC3G expression in DCs was increased in co-cultures of DCs and ApoAct but not by apoptotic resting CD4
+
T cells (ApoRest). Silencing of APOBEC3G in DC abrogated the HIV inhibitory effect mediated by ApoAct. Sequence analyses
of an env region revealed significant induction of G-to-A hypermutations in the context of GG or GA dinucleotides in DNA
isolated from DCs exposed to HIV and ApoAct. Thus, ApoAct-mediated DC maturation resulted in induction of APOBEC3G
that was important for inhibition of HIV-infection in DCs. These findings underscore the complexity of differential DC
responses evoked upon interaction with resting as compared with activated dying cells during HIV infection.
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Introduction
DCs are professional antigen-presenting cells that play a central
role in connecting innate and adaptive immunity[1]. DCs residing
in peripheral tissues engulf both foreign microbial material and
dying cells of the host. Maturation signals are, however, required
for DCs to undergo phenotypic and functional changes to acquire
a fully competent antigen-presenting capacity. Maturation of DCs
is a process that includes a transient increased capacity for antigen
uptake; migration to draining lymph nodes; and simultaneous
upregulation of molecules including chemokine receptors, major
histocompatibility complex (MHC) class I and II molecules, and
co-stimulatory molecules [1,2]. DC maturation is triggered by
CD40 ligand, danger associated molecular pattern released from
certain dying cells and by pro-inflammatory cytokines, such as
tumor necrosis factor-a (TNF-a), IL-1b, IL-6, and interferon-a
(IFN-a) [3]. In addition, infected apoptotic cells may provide a DC
maturation signal through interactions with pattern recognition
receptors including members of the Toll-like receptor (TLR)
family [4–6]. DCs are located in mucosal and lymphoid tissues and
because of their localization in the mucosa, are likely to be among
the first cells to encounter invading HIV particles [7]. It has been
shown that DCs can be infected by HIV and support viral repli-
cation, suggesting that HIV-infected DCs may be a viral reservoir
in vivo [8]. Experiments using human cervical explants models
showed that emigrating DCs had captured HIV and were capable
of transmitting the virus to CD4
+ T cells in trans [9]. In vitro
experiments further support a role for DCs in transmitting HIV to
CD4
+ T cells which was demonstrated to occur both in cis and
trans [7].
DC maturation suppresses HIV infection through multifaceted
mechanisms that involve decreased viral fusion [10], a block of
reverse transcription [11] and a post-integration restriction that
has been proposed to exist at the transcriptional level [3]. There
are several described intrinsic factors that act at discrete steps in
the viral life cycle to mediate suppression of HIV replication in
DCs. These include chemokines and their receptors, which play a
central role in HIV infection and disease progression. HIV uses
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receptors for viral entry [12]. The chemokines MIP-1a, MIP-1b,
and RANTES, which bind to CCR5, have potent anti-HIV
activity [13]. Although many cytokines were initially described as
having anti-HIV activities, subsequent or simultaneous studies
using different experimental conditions have shown that they may
also activate virus production [14,15]. TNF-a was identified as the
predominant inducer of HIV production in supernatants from
both monocyte and lymphocyte cultures [16,17]. The proviral
activity is dependent on the activation of NF-kB present in the
cytoplasm of both monocytes and lymphocytes [18–20]. The dual
activity of TNF-a with regard to HIV replication was later
suggested by a study showing inhibition of HIV replication before
proviral DNA integration [21]. TNF-a was furthermore shown to
induce DC maturation, leading to down-regulation of HIV co-
receptors [22]. Hence, there are several cytokines, including TNF-
a, IFN-c, TGF-b and MCP-1, that have either pro-HIV or anti-
HIV effects depending on the experimental system and/or the
types of cells analyzed [14,15]. In addition type I interferons were
shown to induce the restriction factor APOBEC3G [23]. Members
of the APOBEC family of proteins confer intrinsic immunity to
retroviral infection [24]. APOBEC3G levels are increased upon
DC maturation, suggesting a role for APOBEC3G as a possible
candidate for viral restriction in maturing DCs exposed to HIV
[23,25]. APOBEC3G is restricting HIV replication by deamina-
tion of viral cDNA cytidine during reverse transcription. This will
lead to a characteristic induction of G-to-A hypermutations.
However, some studies suggest deaminase-independent effects by
APOBEC3G proteins interfering with steps in reverse transcrip-
tion or integration (reviewed in [23]).
Uptake by DCs of apoptotic bodies originating from HIV-infected
cells in vitro results in activation of CD4
+ and CD8
+ T cells [26–28].
Antigens contained in apoptotic bodies are introduced into MHC
class Ipresentation pathways for cross-presentationandstimulationof
HIV-specific CD8
+ T cells. We recently demonstrated that activated,
but not resting, apoptotic peripheral blood mononuclear cells
(PBMCs) are able to induce maturation of DCs in terms of up-
regulation of costimulatory molecules (CD80 and CD86) and
induction of pro-inflammatory cytokine release [29]. In the present
study, we determined whether apoptotic CD4
+ T cells support DC
maturation and whether HIV infection interferes with this process.
We show that apoptotic HIV-infected (ApoInf) and uninfected
activated CD4
+ T cells (ApoAct) provide maturation signals to DCs
that result in the release of TNF-a,M I P - 1 a,M I P - 1 b and MCP-1.
Furthermore, upregulation of CD86 molecules in DCs was reduced
in the presence of anti-TNF-a. We further found a significantly
reduced percentage of HIV-infected DCs when they were co-
cultured with ApoAct as compared with DCs co-cultured with
apoptotic resting CD4
+ T cells (ApoRest); this effect was partly
blocked in the presence of anti-TNF-amAbs. We detected upregula-
tion of APOBEC3G mRNA expression in DCs co-cultured with
ApoAct but not with ApoRest. In addition, we demonstrated
induction of G-to-A hypermutations in env-DNA isolated from HIV
infected DCs co-cultured with ApoAct but not with ApoRest, as a
sign of APOBEC3 activity in mature monocyte derived DCs These
findings may have relevance for cell-associated HIV transmission and
pathogenesis, as dying uninfected and HIV-infected cells constitute a
characteristic hall mark in acute and chronic HIV infection [30,31].
Materials and Methods
Human subjects and blood collection
Buffy coats from healthy human blood donors were obtained
from the blood bank at Karolinska University Hospital Huddinge.
Ethical approval was obtained from the medical ethics committee
in Stockholm.
In vitro differentiation of DCs
CD14
+ monocytes were enriched from buffy coats by negative
selection using RosetteSep Human Monocyte Enrichment (1 ml/
10 ml blood; Stem Cell Technologies, Vancouver, BC, Canada).
Monocytes were separated using Lymphoprep density gradient
(Nycomed, Oslo, Norway) and were cultured for 6 days in DC
medium containing RPMI 1640 (GIBCO Life Technologies,
Paisley, United Kingdom), supplemented with 1% HEPES (N-(2-
hydroxyethyl)piperazine-N’-2-ethanesulfonic acid) (GIBCO), 2 mM
L-glutamine (GIBCO), 1% streptomycin (GIBCO), and 1% peni-
cillin (GIBCO), 10% endotoxin-free fetal bovine serum (FBS)
(GIBCO), recombinant human cytokines IL-4 (6.5 ng/ml; R&D
Systems, Minneapolis, MN) and granulocyte-macrophage colony-
stimulating factor (GM-CSF; 250 ng/ml; Peprotech; London,
United Kingdom) to obtain immature DCs [32].
Purification and activation of CD4
+ T cells
CD4
+ T cells were enriched from buffy coats obtained from
whole blood by negative selection using RosetteSep Human CD4
+
T Cell Enrichment (1 ml/10 ml blood; Stem Cell Technologies).
CD4
+ T cells were separated using Lymphoprep density gradient
(Nycomed). Cells were frozen in FBS and 10% dimethylsulfoxide
(DMSO) or were added to flasks containing monoclonal anti-
human CD3 (10 mg/ml; clone OKT 3; Ortho Biotech Inc.,
Raritan, NJ) that had been adhered to the plastic overnight at 4uC
and soluble monoclonal anti-human CD28 (2 mg/ml; L293; BD
Biosciences, San Diego, CA). After 24 hours of stimulation, cells
were frozen in FBS/DMSO. On the day of experiment, frozen T
cells were thawed, washed, and induced to undergo apoptosis by
c-irradiation (150 Gy) as described [29,33-36].
HIV growth and preparation
The HIV isolates HIVBaL (which uses CCR5 receptors) and
HIVIIIB (which uses CXCR4 receptors) were obtained from the
National Institutes of Health (NIH) AIDS Research and Reference
Reagent Program, Division of AIDS, National Institute of Allergy
and Infectious Diseases (NIAID, NIH, Bethesda, MD). HIV
isolates were grown in PBMC cultures stimulated with phytohe-
magglutinin (PHA; 2.5 mg/ml; Sigma, St Louis, MO) and IL-2
(75 IU/ml; Chiron, Emeryville, CA). Primary virus was isolated
from HIV-infected patient blood by co-culture with PHA-acti-
vated donor PBMCs. To concentrate the virus and to minimize
the presence of bystander activation factors in the supernatant that
could induce DC maturation, virus stocks were ultracentrifuged
(138,0006g for 30 minutes at 4uC. (Beckman L-80 Ultra-cen-
trifuge, rotor 70.1; Beckman Coulter, Fullerton, CA), and the virus
pellets were resuspended in RPMI 1640 with 10% FBS to obtain a
virus concentrate. An aliquot of each viral stock was thawed and
titrated for infectivity using a limiting dilution culture method with
PHA-activated PBMCs (mix of 3 different donors) [37]. The 50%
tissue culture infectious dose (TCID50) was calculated by the
method of Reed and Muench as described in [38]. The titers of
virus stocks were 1.7610
6/ml TCID)50 for both HIVBaL and
HIVIIIB. The primary isolates (207 and 208) had a TCID50 of
1.0610
3/ml and 4.0610
4/ml, respectively.
HIV infection of CD4
+ T cells and DCs
Activated (24 hours with CD3 and CD28 monoclonal antibod-
ies (mAbs) as described above) CD4
+ T cells were incubated with
HIVBaL (3000–6000 TCID50) in the presence of IL-2. The
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for the HIV Gag protein p24 at 3, 4, 5, 6, 7, and 10 days after
infection [32,33]. The highest percentage of cells infected was
detected at days 4, 5, and 6; thereafter infection percentages
declined (data not shown). Batches of infected cells collected at day
3–4 were frozen in FBS/DMSO until use. For infection of DCs,
3000–6000 TCID50 of HIVBaL and HIVIIIB, and 500 TCID50 of
the primary isolates were used. The percentage of infected DCs
was determined by intracellular p24 staining after 7 days of
infection.
Quantification of HIV protein in T cells and DCs
The percentage of HIVBaL-infected DCs and CD4
+ T cells was
determined by intracellular staining for p24 [32,33]. Cells were
first stained for cell surface markers and then fixed in 2%
formaldehyde (Sigma) for 10 minutes at room temperature. Cells
were washed in saponin solution consisting of PBS with 2% FBS,
2% HEPES, and 0.1% saponin (Sigma), to allow permeabilization
of the cell surface membrane, and then incubated for 1–2 hours at
4uC with a p24 mAb (clone KC57; Coulter, Hialeah, FL) or the
corresponding isotype control antibody. Intracellular p24 expres-
sion was assessed by a FACSCalibur flow cytometer (Becton
Dickinson, San Jose, CA) and data were analyzed using CellQuest
Software (Becton Dickinson, San Jose, CA).
DC and apoptotic CD4
+ T cell co-cultures
Differentiated, immature DCs were co-cultured with irradiated
CD4
+ T cells at a ratio of 1:2 DC:T cells in DC medium. Con-
ditioned medium (CM) was prepared by co-culturing DCs with
ApoAct for 24 hours. In some experiments, CM was added to the
DC cultures at 40% of the total volume. Supernatants were col-
lected from co-cultures at 4, 8, and 24 hours. The TLR4 agonist
LPS (100 ng/ml; Sigma) was used as a positive control for
activation and maturation of DCs. DCs were exposed to HIVBaL,
and apoptotic cells or CM was added at 0, 2, or 16 hours. For
cytokine blocking experiments, CM was pre-incubated for 2 hours
at 37uC with blocking antibodies alone or in combination (all
obtained from R&D Systems): anti-MIP-1a (clone 14215; 2.5 mg/
ml), anti-MIP-1b (clone 24006; 1 mg/ml), anti-IFN-c (clone
25718; 4 mg/ml), anti-RANTES (clone 21445; 2.5 mg/ml), and
anti-TNF-a (clone 1825; 0.5 mg/ml). In DC/ApoAct co-cultures,
anti-TNF-a was added at the beginning of the co-culture. DCs
were analyzed by flow cytometry for p24 and CD86 expression 7
days after infection.
Phenotypic characterization of DCs and T cells
DCs were stained with the following anti-human mAbs: CD1a
(clone NA1/34; DAKO, Glostrup, Denmark), CD14 (clone
TU ¨K4; DAKO), CD3 (clone SK7; BD Biosciences), CD83 (clone
HB15e; BD Biosciences), and CD86 (clone 2331/FUN-1; BD
Biosciences). T cells were stained with anti-human mAbs CD19
(clone HD37; DAKO), CD3 (clone SK7; BD Biosciences), CD4
(clone RPA-T4; BD Biosciences), CD8 (clone SK-1; BD
Biosciences), CD25 (clone 2A3; BD Biosciences), and CD69
(FN50; BD Biosciences). Cell surface expression was measured by
a FACSCalibur flow cytometer (Becton Dickinson). Co-culture
samples were collected at 72 hours or 7 days, washed, and incu-
bated with the previously mentioned CD1a, CD83, CD86, and
p24 mAbs, as indicated.
Cytokine and chemokine production
Supernatants from apoptotic CD4
+ T cells and DC co-cultures
were analyzed for cytokines and chemokines with the Bio-Plex
assay (Biosource, Nivelles, Belgium). A Luminex reader (Luminex
Corporation, Austin, TX) was then used to simultaneously quan-
tify the concentration of IL-2, RANTES, IL-10, IL-12, TNF-a,
MCP-1, MIP-1a, and MIP-1b in the supernatants.
Quantification of HIV-long terminal repeat (LTR) in DCs
Genomic DNA was extracted from infected DCs using the
QIAamp DNA Mini Kit (Qiagen Inc., Valencia, CA). HIV-LTR
sense and anti-sense primer sequences were 59-GCCTCAA-
TAAAGCTTGCCTTGA-39 and 59-GGGCGCCACTGCTAG-
AGA-39. The probe sequence was 59-6-FAM-CCAGAGTCACA-
CAACAGACGGGCACA-TAMRA-39, and the resulting amplicon
was 121 bp. Primer and probe design was based on published
sequences [39] and were from Applied Biosystems, Foster City, CA.
Real-time PCR reactions were performed in 10-ml reactions (Applied
Biosystems) using the 7500 Real-Time PCR System (Applied
Biosystems). For absolute quantification of HIV-LTR, a control
plasmid was constructed by cloning the 121-bp HIV-LTR amplicon
into pCRH4-TOPOH (Invitrogen Life Science). Plasmid copy
number was quantified as described [40].
HIV-1-integration Alu-PCR assay
Total cell DNA was isolated at 72 h after infection with a
QIAamp blood isolation kit (Qiagen). Integrated HIV-1 DNA was
measured by two-step Alu-PCR [6]. In the first round of pre-
amplification PCR, Alu-LTR sequences were amplified with an
HIV-1-specific primer (LTR R region) in combination with a
primer that anneals to the abundant genomic Alu repeats. The
HIV-1-specific primer was extended with a marker region at the 59
end, which was used for specificity in the second-round PCR. The
second round was nested quantitative real-time PCR of the first-
round PCR products with primers annealing to the aforemen-
tioned marker region in combination with a HIV-1-specific primer
(LTR U5 region). Primer sequences were as follows: first round,
HIV-1 LTR R forward, 59-ATGCCACGTAAGCGAAACTG-
CTGGCTAACTAGGGAACCCACTG-39 (marker sequence un-
derlined); Alu reverse, 59-TCCCAGCTACTGGGGAGGCTG-
AGG-39; second-round marker forward, 59-ATGCCACGTAA-
GCGAAACTG-39; HIV-1 LTR U5 reverse, 59-CACACTGAC-
TAAAAGGGTCTGAGG-39. Samples were assayed at two con-
centrations to ensure that PCR inhibitors were absent. Dilutions
were prepared with genomic DNA from uninfected cells to ensure
that the number of Alu sites per reaction mixture remained
constant. For monitoring of the signal contributed by non-
integrated HIV-1 DNA, the first-round PCR was also done with
the HIV-1-specific primer alone as a control. HIV-1 integration
was normalized relative to GAPDH DNA. For relative HIV-1
integration, the value obtained for BaL-infected DCwere set to
1 for each donor and compared with DC from the same donor
co-cultured with ApoAct or ApoRest.
Real-Time PCR analysis and silencing of APOBEC3G
RNA was extracted either from freshly isolated DCs or from
DCs co-cultured with LPS or with ApoRest or ApoAct as
described above. RNA was isolated using the RNeasy Mini Kit
(Qiagen). RNA was reverse transcribed using High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems). Amplifi-
cation of APOBEC3G, 18s RNA and GAPDH cDNA was
performed using the 7500 Real-Time PCR System (Applied
Biosystems) and 6-carboxyfluorescein dye-labeled TaqMan MGB
probes and primers (Applied Biosystems) [41-43]. We did a
homology BLAST for the primer-probe, which is highly specific to
APOBEC3G. The reference sequence ID is NM_021822.3, NCBI
chromosome location is Chr. 22 - 39473010 – 39483748. The
Apoptotic Activated T Cells Inhibit HIV in DCs
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APOBEC3G and the amplicon length was 80 bp. Cycle threshold
values for APOBEC3G were normalized to the value for GAPDH
or 18S in control experiments. Data are presented as fold changes
in mRNA copy number in the DCs co-cultures as compared to
mRNA in DCs cultured in medium only. DCs were transfected
with 25 nM siRNA with the transfection reagent DF4 (Dharma-
con, Thermo Fisher Scientific) and were used for experiments
36 hoursaftertransfection[6]. The siRNA(SMARTpool;Dharma-
con) specific for APOBEC3G was purchased from Dharmacon (M-
013072-00). Non-targeting siRNA (D-001206-13; Dharmacon)
served a control. This protocol resulted in a transfection efficiency
of nearly 100%, as determined by flow cytometry of cells transfected
with siGLO RISC-Free Control siRNA (D-001600-01; Dharma-
con), and 79–90%of silencing of expression of APOBEC3G was
achieved as verified by real-time PCR analysis.
HIV-1 env sequencing and analysis. Total cell DNA was
isolated 72 h after infection with a QIAamp DNA mini kit
(Qiagen). HIV-1 env V1-V5 gene region was amplified by
performing high-fidelity nested PCR using an EasyA kit
(Stratagene). The primers used were as follows: Round 1
(product size 1415 bp) Forward 59 TTGCAATAGAAAAATT-
CTCCTC 39, Reverse (59CCTGGTGGGTGCTACTCCTA 39).
Round 2 (product size 1098 pb) Forward 59 CCATGTGTA-
AAGTTAACCCC 39, Reverse, 59 ATGAGGGACAATTGAG-
AAGTGTCTAG 39, PCR condition as described in [44].
Amplicons were purified by using a high pure PCR product
purification kit (Roche), and cloned into the TA cloning vector
provided in a TOPO TA cloning kit (Invitrogen) in accordance
with the manufacturer’s instructions. Plasmids were isolated using
Genejet plasmid mini prep kit (Fermentas) and the plasmids were
sent to Eurofins MWG Operon, Germany for sequencing. Primers
M13 forward (59 GTAAAACGACGGCCAG 39) and M13 reverse
(59 CAGGAAACAGCTATGAC 39) were used for sequencing.
G-to-A mutations were analyzed by using the program Hypermut
2.0 that is freely available at http://www.hiv.lanl.gov/content/
sequence/HYPERMUT/hypermut.html [45].
Results
Up-regulation of co-stimulatory molecules on DCs after
co-culture with apoptotic activated CD4
+ T cells;
uninfected (ApoAct) and HIV-infected (ApoInf)
We previously demonstrated that apoptotic anti-CD3/CD28–
activated PBMCs, but not apoptotic resting PBMCs, can induce
DC maturation [29]. Here we first investigated whether apoptotic
HIV-infected activated CD4
+ T cells (ApoInf) are able to induce
DC maturation. Primary CD4
+ T cells were activated with CD3
and CD28 mAbs for 24 hours before infection with HIV. The
efficiency of T cell activation was determined by expression of
CD25 and CD69. After activation, the percentage of CD25
+CD4
+
T cells was 49–66%, and the percentage of CD69
+CD4
+ T cells
was 44–48%, as compared with 0.7–13% and 0.4–6.3%,
respectively, before activation (data not shown). We next infected
activated CD4
+ T cells with HIVBaL. The infection efficiency, as
determined by intracellular p24 staining, was 28–43% (data not
shown). Batches of cells were frozen, and on the day of experi-
ment, cells were thawed, washed, and induced to undergo
apoptosis by c-irradiation as described [29,33–36]. In the majority
of experiments, c-irradiated T cells were added to the DC cultures
immediately after radiation exposure to allow early apoptotic
events to occur in the co-cultures.
We used in vitro–differentiated monocytes cultured for 6 days in
the presence of IL-4 and GM-CSF as the source of human
immature DCs, which are defined by the expression of CD1a;
absence of CD14; and low expression of CD40, CD80, CD86, and
CD83 [29,32]. These immature DCs were co-cultured with
ApoAct or ApoInf for 72 hours or 7 days and then analyzed for
expression of the co-stimulatory molecule CD86 (Figure 1). Repre-
sentative flow cytometric analyses are depicted in Figure 1A, and a
summary of 11 donors is shown in Figure 1B. The percentage of
CD86
+ DCs was 91.162.5% after LPS stimulation and the
background medium control was 26.965.3% after 72 hours. DCs
exposed to HIVBaL viral particles did not significantly up-regulate
CD86 after 72 hours or 7 days of culture as compared with the
medium control (Figure 1B) although some donors had a low
induction of CD86 (Figure 1A). It should be noted that the virus
stock used in the present study was ultra-centrifuged to remove cell
debris and possible bystander soluble factors. Co-culture with
ApoAct or ApoInf, on the other hand, resulted in a robust and
significant induction of CD86 as compared with medium control
both after 72 hours (p,0.001) and 7 days (p,0.01 and p,0.05,
respectively) of culture (Figure 1B). It is conceivable that the local
milieu in vivo upon DC encounter with infected or uninfected
apoptotic cells will contain viral particles. We therefore investi-
gated whether this mechanism for induction of DC maturation
was functional in the presence of viral particles. We found that the
maturation signal provided by the ApoAct or ApoInf occurred
even in the presence of free HIVBaL, and the efficiency of induced
CD86 expression was comparable to that of the positive control.
The expression of CD83, another molecule associated with DC
maturation and functional antigen-presenting capacity, showed an
expression pattern that was similar to that of CD86 but with a
tendency of lower expression than CD86. These findings show
that both ApoAct and ApoInf are able to provide a maturation
signal to immature DCs even in the presence of exogenous HIV.
Cytokines and chemokines are secreted after co-culture
of DCs with ApoAct and ApoInf
To address whether cytokine production was induced in DCs
after exposure to ApoAct and/or ApoInf, we collected superna-
tants from the co-cultures after 4, 8 and 24 hours and used a
multiplexed cytokine assay for simultaneous analyses of MIP-1a,
MIP-1b, TNF-a, IL-10, IL-12, and MCP-1. There was a
significant induction of TNF-a from the co-cultures with apoptotic
anti-CD3– and anti-CD28–activated CD4
+ T cells either unin-
fected (p,0.001) or HIV-infected cells (p,0.001), as compared
with medium control after 24 hours of co-culture (Figure 2). TNF-
a was detected in co-culture supernatants even when exogenous
HIVBaL was present in the cultures and reached quantities in a
similar range as LPS stimulation. We did not detect any secretion
of the cytokines analyzed from the ApoAct per se (denoted as ‘‘no
DC’’; Figure 2). Co-cultures with apoptotic resting CD4
+ T cells
(ApoRest) or apoptotic neutrophils did not result in any secretion
of the mentioned cytokines (data not shown and [29]). We could
not detect any significant production of IL-10 or IL-12p70 after
co-culturing with ApoAct, regardless of infection status (data not
shown). Production of the chemokine MCP-1, which enhances
mucosal IgA secretion and cytotoxic T cell responses [46], was
detected in supernatants from co-cultures of DCs and ApoAct
(p,0.001 as compared with medium control; Figure 2). MCP-1
production also occurred in the presence of exogenous HIVBaL.
There were significantly increased quantities of MCP-1 secreted in
co-cultures with ApoAct as compared with LPS (p,0.05). We also
detected significant induction of MIP-1a and MIP-1b expression
in co-cultures with ApoAct, regardless of HIV infection (Figure 2).
Altogether, these findings suggest that both ApoAct and ApoInf
Apoptotic Activated T Cells Inhibit HIV in DCs
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production in DCs.
Reduced percentage of HIV-infected DCs detected in
co-cultures with ApoAct but not ApoRest
The finding that several cytokines were released into the super-
fonatants, including those with anti-HIV activity [13], prompted
us to ask whether co-culturing with ApoAct could influence the
efficiency of virus infection in DCs. We measured HIV infection
by determining the percentage of cells expressing intracellular p24
antigen, as described (Figure 3A) [32,33]. Addition of 39-azido-39-
deoxythymidine (AZT) to the DC cultures inhibited detection of
p24, which showed that intracellular p24 as detected by flow
cytometry was the result of productive infection in DCs [32].
Immature DCs were exposed to HIVBaL; there was large vari-
ability between donors with regard to HIV infection efficiency,
ranging from 4.0 to 46.4% after 7 days (Figure 3B). Co-culture of
DCs with ApoAct, either uninfected or HIV-infected, resulted in a
significantly reduced percentage of p24
+ DCs as compared with
DCs exposed only to HIVBaL (Figure 3B,C; p,0.01 and p,0.05,
respectively). There was no significant reduction in p24 expression
in DCs after exposure to ApoRest (Figure 3D). We detected
similar induction of CD86 expression and reduction in percentage
of p24 positive DCs using either autologous or allogeneic ApoAct
(Figure S1). The critical step to gain the capacity to induce DC
maturation and reduction in HIV-infection was the activation step
(Figure 3D).We also measured HIV infection efficiency by
quantitative PCR. There was an almost tenfold reduction in viral
DNA copies in samples co-cultured with ApoAct but not ApoRest
(Figure 3E). Alu-PCR was used to determine the relative propor-
tion of integrated HIV DNA to investigate whether the inhibition
occurred pre- or post-integration. The values obtained in the HIV
Figure 1. ApoAct or ApoInf induce CD86 and CD83 expression in human DCs. Human in vitro–differentiated monocytes cultured for 6 days
in the presence of IL-4 and GM-CSF were used as the source of human immature DCs. (A) Immature DCs were co-cultured with apoptotic allogeneic
CD4
+ T cells for 72 hours or 7 days and then analyzed for expression of CD86 molecules by flow cytometry. Gates were set on large CD1a
+CD3
– cells.
LPS, which is a potent DC activator, was used as a positive control, and DCs cultured in medium only were used as a negative control. Immature DCs
were cultured in medium alone or in the presence of LPS (LPS), HIVBaL (HIV), apoptotic anti-CD3– and anti-CD28–activated CD4
+ T cells (ApoAct),
ApoAct in the presence of exogenous HIVBaL (ApoAct+HIV), or apoptotic HIVBaL-infected activated CD4
+ T cells (ApoInf). Representative flow
cytometry data from one donor after 7 days of co-cultures are shown. (B) The average percentages of CD86
+ DCs 6 SD for 11 donors and of CD83
+
DCs 6 SD for 7 donors are depicted. Data from at least four independent experiments are included. Significant differences compared with medium
control were assessed by the non-parametric Mann-Whitney U-test, and significance is indicated by *p,0.05, **p,0.01, and ***p,0.001.
doi:10.1371/journal.pone.0021171.g001
Figure 2. Cytokine and chemokine released from DCs exposed to ApoAct or ApoInf. Immature DCs were co-cultured with activated
apoptotic allogeneic CD4
+ T cells for 24 hours, and culture supernatants were analyzed for the presence of TNF-a, MCP-1, MIP-1a and MIP-1b. DCs
were cultured in medium alone (negative control) or in the presence of LPS, which is a potent DC activator (positive control). DCs were exposed to
HIVBaL (HIV), anti-CD3– and anti-CD28–activated apoptotic CD4
+ T cells (ApoAct), ApoAct in the presence of HIVBaL (ApoAct+HIV), apoptotic anti-CD3–
and anti-CD28–activated CD4
+ T cells infected with HIVBaL (ApoInf), or ApoInf in the presence of exogenous HIVBaL (ApoInf+HIV). Control wells
included ApoAct without any DCs (no DC). The results shown are the mean 6 SD from at least seven donors except for the MCP-1 analysis with
ApoInf which shows data from two donors. Significant differences compared with medium control were assessed by non-parametric Mann-Whitney
U-test and Kruskal-Wallis test with Dunn’s multiple comparison test and are indicated by *(p,0.05), ** (p,0.01) and *** (p,0.001), respectively. Non-
significant, NS.
doi:10.1371/journal.pone.0021171.g002
Apoptotic Activated T Cells Inhibit HIV in DCs
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21171Figure 3. Reduced percentage of HIV-infected DCs detected after co-culturing with ApoAct but not ApoRest. Immature DCs were
exposed to HIVBaL (HIV), apoptotic anti-CD3– and anti-CD28–activated allogeneic CD4
+ T cells (ApoAct), ApoAct in the presence of HIVBaL
(ApoAct+HIV), apoptotic anti-CD3– and anti-CD28–activated allogeneic CD4
+ T cells infected with HIVBaL (ApoInf), or ApoInf in the presence of
exogenous virus (ApoInf+HIV). The percentage of infected DCs was assessed by flow cytometry analysis of intracellular p24 staining after 7 days. (A)
Representative results from one donor and (B) paired results from eleven donors, both after 7 days of infection, are shown. (C) The average
percentage of p24
+ DCs 6 SD after 7 days in eight donors is shown. (D) Data comparing the percentage of p24
+ DCs in the presence of HIVBaL after
co-culturing with ApoAct (ApoAct+HIV) and apoptotic resting CD4
+ T cells (ApoRest+HIV). Results are shown as the mean 6 SD of p24
+ DCs from
additional paired eight donors. Significant differences were assessed by the non-parametric Wilcoxon test and are indicated by *p,0.05, **p,0.01,
and ***p,0.001. (E) The number of viral DNA copies/100 cells as assessed by quantitative real-time PCR for three donors is shown. (F) Integration of
HIV DNA was assessed by Alu-PCR. Data depict five different donors. Significant differences were assessed by the non-parametric test and are
indicated by *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0021171.g003
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reduced value obtained in DCs co-cultured with ApoAct, sug-
g e s t i n gt h a tab l o c ko c c u r r e da tl e a s ti np a r tp r i o rt oH I Vi n t e g r a t i o n
(Figure 3F). We next performed dose-response experiments to
investigate the DC/ApoAct concentration required to obtain a
reduced percentage of infection in DCs. DCs were co-cultured with
serially diluted ApoAct (Figure S2). We detected an increasing
percentage of p24
+ DCs with decreasing numbers of ApoAct.
We also performed kinetic experiments by first incubating DCs
with HIVBaL for 30 minutes, 1 hour, or 2 hours followed by
addition of ApoAct. We observed the same reduction in p24
expression if the DCs were exposed to the virus for 30 min, 1 hour
or 2 hours prior to addition of ApoAct (Figure S3A). Conversely,
DCs were first exposed to ApoAct for 30 minutes, 1 hour, or
2 hours before addition of HIVBaL. Again, the percentages of p24
+
DCs were similar for all three pre-incubation time points (Figure
S3A). We also performed experiments with longer kinetics by
adding ApoAct 16 hours after HIVBaL infection of DCs or adding
ApoAct 16 hours before infection. Again, reduced percentage of
infected DCs was detected when they were co-cultured with
ApoAct under any of these conditions (Figure S3B). ApoAct-
mediated inhibition of HIV in DCs was also detected using three
additional virus isolates (HIVIIIB and primary isolates 207 and
208) (Figure S4).
TNF-a released in conditioned media from DC/ApoAct
partially blocks HIV infection in DCs
To assess whether conditioned medium (CM) collected from
DC/ApoAct co-cultures reduces HIV infection, we collected
supernatants after 24 hours of co-culture to use as CM. Different
amounts of CM were added to cultures of immature DCs and
HIV. There was a dose-dependent response in the reduction of
p24 expression in DCs after exposure to CM (Figure 4A). To
further elucidate the role of CM mediated reduction of HIV
infection in DCs and to investigate possible candidate cytokines
and/or chemokines for the effect, we added CM from DC/
ApoAct cultures to DCs exposed to HIVBaL (Figure 4B,C). A
reduced p24 expression was detected in DCs exposed to HIV and
CM as compared with DCs exposed to only HIV (p,0.05). The
addition of blocking antibodies to MIP-1a, MIP-1b, IFN-c and
RANTES to the CM did not restore p24 expression, whereas
addition of blocking antibody to TNF-a did (Figure 4B). CM
added 2 hours or 16 hours after HIV exposure did not sig-
nificantly reduce p24 expression in DCs (Figure 4C). However,
ApoAct added 2 hours or 16 hours after HIV exposure reduced
HIV p24 expression in DCs (Figure 4D; p,0.001). The HIV
inhibitory effect by ApoAct was partially lost in the presence of
TNF-a mAb (Figure 4D). In addition, the TNF-a mAb blocked
CM-mediated up-regulation of CD86 in DCs (Figure 4E; p,0.05).
We next treated immature DCs with different concentrations
recombinant TNF-a and exposed them to HIV. There was a dose-
dependent inhibition of HIV infection in DC by TNF-a where the
highest concentration (25 ng/ml) showed an effective inhibition
(Figure 4F). The HIV inhibitory effect by TNF-a was lost in the
presence of TNF-a mAb (Figure 4F). These data show that TNF-a
treatment can inhibit HIV infection in these DCs and that the
HIV inhibitory effect by ApoAct can be partially explained by
release of TNF-a.
APOBEC3G-mediated HIV inhibition in DCs exposed to
ApoAct
The anti-viral factor APOBEC3G is induced upon DC
maturation by LPS [25]. We therefore investigated whether
APOBEC3G was induced after ApoAct-mediated DC maturation.
RNA was prepared from DC co-cultures after 2, 6, 24, and
48 hours, and APOBEC3G expression was assessed by real-time
PCR. We detected induction of APOBEC3G after LPS stimula-
tion and after ApoAct exposure in DCs when analyzed at the
time points 6, 24 and 48 hours. However, we did not detect
APOBEC3G after 2 hours of incubation, which showed that the
APOBEC3G detected was not derived from the ApoAct. DC co-
cultures with ApoRest did not promote induction of APOBEC3G
(Figure 5A). In control experiments, we used two different house-
keeping genes; GAPDH and 18S RNA, to normalize the data and
obtained a similar pattern of upregulation of APOBEC3G after
stimulation with either LPS or ApoAct (Figure S5).
To investigate whether APOBEC3G induced by ApoAct
played a role in the HIV inhibitory effect in DCs, we silenced
APOBEC3G using siRNA. The transfection procedure per se,
neither altered the expression levels of APOBEC3G, nor induced
secretion of TNF-a (Figure S6). The efficiency of silencing as
revealed by real-time PCR was in the range of 79–90% in four
different DCs donors co-cultured with ApoAct. The silencing of
APOBEC3G resulted in a significantly increased p24 frequency
(p,0.03 Wilcoxon paired test) that returned to baseline infection
levels (Figure 5B). These data show induction of APOBEC3G
expression in DC upon co-culture with ApoAct but not ApoRest.
Moreover, siRNA analyses revealed that the HIV inhibitory effect
mediated by ApoAct can largely be explained by induction of
APOBEC3G in DCs. To verify that APOBEC3 proteins exerted a
function to restrict HIV infection in the DC, we sequenced a
region in env and measured the frequencies of G-to-A mutations
using the program HYPERMUT 2.0. We sequenced 6 clones
from HIVBa-L infected DC of which one was used as reference
sequence, 35 clones from HIVBa-L infected DC co-cultured with
ApoRest and 26 from DC co-cultured with ApoAct (Table 1). In
total 21,000 base pairs were sequenced from ApoRest co-cultures
and 15,600 from ApoAct. None of the clones sequenced from
ApoRest co-cultures were found to have significant induction of G-
to-A hypermutations according to the HYPERMUT program,
while 3 clones had significant p,0.05 Fisher exact p-value in co-
cultures with ApoAct. The total number of G-to-A mutations
detected in ApoRest co-cultures were 39 while 201 mutations were
detected in clones derived from ApoAct co-cultures. The average
numbers of G-to-A mutations per 100 base pairs were 0.09 and
1.288 in the ApoRest and ApoAct co-cultures, respectively. G-to-A
mutations were detected both in the GG and GA context. There
was a significant difference (p,0.03 unpaired t-test) in the muta-
tion frequency in clones obtained from ApoRest DC co-cultures
compared with ApoAct (Figure 5C). These data demonstrate signs
of APOBEC3G activity in DCs after co-culture with ApoAct.
Discussion
Infection of DCs is likely to be an important contributor to the
spread of HIV by capturing virus at sites of viral entry followed by
migration to lymphoid tissues, which constitute an optimal site
for HIV transmission to T cells [30]. Production of HIV can be
blocked by exposure of DCs to maturation stimuli such as for
example LPS [3,10,48]. Here we have demonstrated that apo-
ptotic activated CD4
+ T cells (ApoAct), either uninfected or
recently HIV-infected (ApoInf), induce expression of co-stimula-
tory molecules, release of cytokines as well as reduce HIV infection
in DCs, whereas unactivated apoptotic CD4
+ T cell (ApoRest) do
not. We show that induction of the restriction factor APOBEC3G
was important for the antiviral activity in the DCs. However, these
findings do not preclude involvement of other restriction factors
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implications for viral transmission as DCs are likely to be one of
the first target cells upon transmission when encountering infected
cells and/or free virus.
We found significantly reduced HIV infection in DCs that had
been co-cultured with ApoAct but not in DCs co-cultured with
ApoRest. It was previously suggested that alloantigen-induced
immune responses may reduce HIV susceptibility in CD4
+ T cells
[47,49]. In the present study, we show that both allogeneic and
autologous ApoAct are able to provide DCs with a maturation
signal; however, a prerequisite for the induction of DC maturation
and anti-viral activity was that both the allogeneic and autologous
Figure 4. TNF-areleased in co-cultures of DC and ApoAct mediate partial reduction in HIV infection and an increase in the
percentage of CD86
+ cells. (A) Conditioned medium (CM) was collected from co-cultures of DCs and ApoAct after 24 hours. Immature DCs were
exposed to the supernatants in increasing concentrations (final volume, 1 ml) in the presence of HIVBaL. The percentage of intracellular p24
+ cells was
measured by flow cytometry after 7 days. One representative experiment out of two is shown. Two replicates were used to generate mean 6 SD. No
statistical analyses were performed for the CM dose-response analyses. (B) DCs were exposed to HIVBaL (HIV); conditioned medium (CM) from DC and
ApoAct co-cultures; or blocking mAbs to RANTES, MIP-1a, MIP-1b, and IFN-cmAb mixor to TNF-aa-TNF-a). The percentage of HIV-infected DCs was
measured by flow cytometry in cells from eight donors. Significant differences were assessed by the non-parametric Wilcoxon matched-pairs test and
are indicated by *p,0.05. (C) DCs were exposed to HIV, and CM was added at the same time as HIV (0 hours) or after 2 or 16 hours of incubation
before assessment of intracellular p24 by flow cytometry after 7 days in five donors. Significant differences were assessed by the non-parametric
Mann-Whitney U-test and are indicated as **p,0.01. (D) DCs were exposed to HIV and co-cultured with ApoAct added at the same time (0 hours) or
after 2 or 16 hours after HIV infection in six donors. Significant differences were assessed by the non-parametric Mann-Whitney U-test and are
indicated as ***p,0.001. The experiments were carried out in the presence or absence of blocking TNF-a mAbs in three donors and no statistical
analyses were performed. Assessments of intracellular p24 by flow cytometry were performed 7 days after HIV exposure. (E) DCs were exposed to CM
with or without simultaneous HIV exposure in the presence or absence of blocking TNF-a mAb, and the percentage of CD86
+ cells was measured by
flow cytometry after 7 days in five donors. Significant differences were assessed by the non-parametric Mann-Whitney U-test and are indicated as
*p,0.05. (F) DCs were exposed to HIV in the presence of decreasing concentrations of rTNF-a (iii=25 ng/ml, ii=2500 pg/ml, i=250 pg/ml) with or
without simultaneous addition of TNF-a mAb. Assessments of intracellular p24 by flow cytometry were performed 7 days after HIV exposure. Data
represent mean+SD from two donors obtained from one representative experiment out of three.
doi:10.1371/journal.pone.0021171.g004
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co-culturing with DCs. There was no difference in HIV-infected
or uninfected ApoAct to induce DC maturation or cytokine release
and that there was no clear induction of DC maturation by the
virus itself-rather it was the activated apoptotic cell component
that made a difference. It should be noted that we removed cell
debris from the virus preparations to avoid possible contaminating
dead cells from the activated PBMCs used for viral growth.
We also show that part of the anti-HIV activity is mediated by
TNF-a released into the supernatant after co-culture with ApoAct.
TNF-a is an example of a cytokine that can differentially inhibit or
promote HIV replication depending on the target cell type, which
adds to the complexity of events occurring in vivo [14]. We detected
up-regulation of APOBEC3G mRNA expression in the DC co-
cultures with ApoAct indicating that inhibition might occur at
least in part at the transcriptional level [25,50]. Furthermore, PCR
analyses showed that the amount of HIV-DNA present in DCs
after co-culture with ApoAct is lower as compared to DCs co-
cultured with ApoRest, which is in concordance with these
findings, although it should be pointed out that there was not a
Figure 5. APOBEC3G mRNA expression and G-to-A hypermutations are induced after co-culturing with ApoAct but not ApoRest.
(A) Real-time PCR was used to determine fold changes in mRNA for APOBEC3G in DCs co-cultured with LPS, resting apoptotic allogeneic CD4
+ T cells
(ApoRest), or activated apoptotic allogeneic CD4
+ T cells (ApoAct). mRNA levels were compared with mRNA obtained from DCs cultured in medium
at different time points (2 hours, 6 hours, 24 hours, and 48 hours). Data represent the mean 6 SD from four different donors. Real-time PCR analyses
of the 24 hours samples were repeated three times with similar values obtained. Significant differences were assessed by non-parametric Kruskal-
Wallis test with Dunn’s Multiple Comparison Test and are indicated by *p,0.05, **p,0.01, and ***p,0.001. Non-significant, NS. (B) Intracellular p24
expression was measured by flow cytometry in DC exposed to HIV, HIV and ApoRest, HIV and ApoAct non-targeted siRNA or in DC treated with
APOBEC3G siRNA (siA3G) prior to exposure to HIV and ApoAct. Data represent mean6SD from six donors and analyses were performed seven days
after infection. Significant differences were assessed by the non-parametric paired Wilcoxon test and are indicated as *p,0.05. (C) G-to-A mutations
in HIV-1 env clones. HIV-1 env sequences were generated from HIVBaL infected DCs co-cultured either with ApoRest or ApoAct. G-to-A mutation
frequencies as compared with a HIVBaL sequence obtained from DCs cultured with the same stock of HIVBaL were measured in clones from HIVBaL
infected DCs co-cultured either with ApoRest (n=35) or ApoAct (n=26). Significant differences were assessed by the t-test (unpaired), and
significance is indicated by *p,0.03.
doi:10.1371/journal.pone.0021171.g005
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+ cells in the cultures. In
addition, our data suggests that the inhibition was occurring both
pre- and post-integration. We showed that the anti-retroviral
restriction factor APOBEC3G was important for the anti-viral
effect in the present system by silencing APOBEC3G in DCs prior
to addition of HIV and ApoAct. Signs of APOBEC3 activity were
measured by sequence analyses of a region in env, which revealed
significant induction of G-to-A hypermutations in co-cultures with
ApoAct but not ApoRest. Of note is that the mutations occurred
both in a GG and GA context, which implies that the mutations
were induced at least in part by APOBEC3G as GG dinucleotides
are target sites specific for APOBEC3G [23]. APOBEC3A was
also reported to induce G-to-A mutations in a GG context but
there is currently little data showing a HIV restricting role for
APOBEC3A [23]. Several family members of the APOBEC3
family were reported to induce G-to-A hypermutations leading to
HIV restriction in a GA context of which APOBEC3F is well
studied [23]. The present system used a complete HIVBaL with
capacity to produce Vif, a protein know to counteract the antiviral
effect by APOBEC3G [23]. We observed the antiviral activity
after a 7-10 fold increase in APOBEC3G mRNA expression,
which appeared sufficient to restrict HIV-1 replication in the DCs.
We previously reported that apoptotic PBMCs obtained after
24 hours of activation with either CD3/CD28 mAbs or PHA
efficiently support DC maturation, while 4 days of PHA activation
prior to apoptosis induction resulted in a reduced capacity
(although still readily detected) to induce CD86 expression [29].
We therefore here activated CD4
+ T cells with CD3/CD28 mAbs
for 24 hours and induced apoptosis no more than 3–4 days after
initial T cell activation in either uninfected or HIV infected CD4
+
T cells. Hence, we induced apoptosis before extensive HIV-
mediated apoptosis occurred in the cultures. Longer exposures to
activation or activation induced cell death as well as resting
apoptotic cells do not promote DC maturation and such cells are
instead involved in peripheral tolerance mechanisms [29,51–53].
Cell death is a hallmark of HIV pathogenesis [31]. SIV infection
is accompanied by an early depletion of CD4
+ T cells in the gut of
macaques, and progression to AIDS is characterized by depletion
of CD4
+ T cells [54]. However, it is not only HIV-infected cells
that die during HIV infection. There is also a massive depletion of
non-infected bystander cells. HIV-mediated bystander killing was
suggested to occur through viral molecules, such as Nef, Tat, Vpr,
Vpu, Vif, and Env [55]. Increased apoptotic cell death occurs
during HIV infection, but the question of which type of cell death
that is induced in HIV-infected cells in vivo is still somewhat
controversial [31,56]. It is largely unknown whether the HIV-
infected cells that undergo cell death in vivo are dying an immu-
nogenic cell death. Nevertheless, the contribution of different
apoptotic cells during HIV infection in vivo is likely to be complex
and the integrated net effect may in part depend on whether the
apoptotic cells are dying in a state when they are able to induce
cytokine production and DC maturation. Hence, we propose to
make a clear distinction between recently activated cells, cells that
have been activated for a prolonged period before apoptosis, and
resting apoptotic T cells regarding subsequent DC-induced re-
sponses. The data presented here suggest that apoptotic CD4
+ T
cells that were efficiently activated prior to their cell death may
be an important mechanism to reduce HIV infection of DCs.
Aberrant immune activation is another characteristic hall mark of
HIV infection [57] and it remains to be investigated whether the
apoptotic lymphocytes formed during HIV infection has capacity
to reduce HIV infection in DCs.
Together these findings show that apoptotic activated CD4
+ T
cells, either uninfected or HIV-infected, have the capacity to
induce DC maturation and cytokine release of TNF-a, MIP-1a,
MIP-1b, and MCP-1. In addition, we detected a reduced percent-
age of HIV-infected DCs after exposure to ApoAct or conditioned
media from DC/ApoAct co-cultures but not with ApoRest. We
revealed that TNF-a was at least partially mediating the
maturation and reduced HIV infection in DCs. We could show
that the anti-viral effect induced by ApoAct was largely dependent
on upregulation of the restriction factor APOBEC3G in the DCs
leading to induction of G-to-A hypermutations. These findings
have implications for transmission of HIV and HIV pathogenesis
involving interactions between HIV, apoptotic cells and DCs.
Supporting Information
Figure S1 Increase in the percentage of CD86
+ cells and
reduced percentage of HIV-infected DCs after exposure
to either autologous or allogeneic ApoAct. (A) The capacity
to induce CD86 expression in DCs by either autologous
(AutoApoAct) or allogeneic (AlloApoAct) apoptotic anti-CD3–
and anti-CD28–activated CD4
+ T cells was measured by flow
cytometry after 72 hours in co-culture. The mean 6 SD from nine
donors is shown. (B) The capacities of AutoApoAct and AlloApoAct
Table 1. Summary of G-to-A mutation frequencies in HIV-1 env sequences obtained from HIVBaL infected DC co-cultures.
Item Analyzed DC co-cultured with ApoRest DC co-cultured with ApoAct
Total no. of clones
sequenced
35 26
Total no. of base pairs
sequenced
21,000 15,600
Total no. of clones with
Fisher Exact p-value ,0.05
03
Total no. of G-to-A
mutations
39 201
No. of G-to-A mutations
(GG context)
86 0
No. of G-to-A mutations
(GA context)
11 40
Avg no. of G-to-A
mutations/100 bp
0.090 1.288
doi:10.1371/journal.pone.0021171.t001
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depicted as the mean 6 SD from seven donors. Significant
differences were assessed by the non-parametric Mann-Whitney U-
test and are indicated by *p,0.05. Non-significant differences, NS.
(EPS)
Figure S2 Dose-response effect of ApoAct on the per-
centage of HIV-infected DCs. A dose-response assessment
was performed by adding decreasing amounts of ApoAct
(allogeneic) starting with a 1:1 DC:ApoAct ratio. The number
of DCs was kept constant, and the ApoAct were serially diluted
(n=4). HIV p24 expression in DCs was assessed by flow
cytometry after 7 days. Data represent the mean 6 SD from
four different donors.
(EPS)
Figure S3 Reduced percentage of HIV infection in DCs
co-cultured with ApoAct both pre- and post-HIVBaL
exposure. Immature DCs were exposed to HIVBaL (HIV) or
both HIV and apoptotic anti-CD3– and anti-CD28–activated
allogeneic CD4
+ T cells (ApoAct). (A) ApoAct were added at the
same time as the virus (ApoAct+HIV) or at 30 minutes, 1 hour, or
2 hours prior to addition of HIV. Conversely, in some cultures the
DCs were first incubated with HIV for 30 minutes, 1 hour, or
2 hours prior to addition of ApoAct. The percentage of infected
DCs was assessed by flow cytometry of intracellular p24 staining
after 7 days. The resulting mean 6 SD from four donors is shown.
(B) Longer kinetic experiments were also performed by incubating
DCs with HIV for 16 hours before adding the ApoAct, or by
incubating the DCs for 16 hours with ApoAct before adding the
virus. The mean 6 SD from four donors is shown. No statistical
analyses were performed.
(EPS)
Figure S4 ApoAct inhibit infection of different HIV
isolates in DCs. Immature DCs were exposed to HIVBaL;
HIVIIIB; or two different primary isolates, 207 and 208, in the
presence (white bars) or absence (black bars) of ApoAct (allogeneic).
The percentage of infected DCs was assessed by flow cytometry of
intracellular p24 staining after 7 days. Data represent the mean 6
SD from two different donors.
(EPS)
Figure S5 APOBEC3G mRNA expression are induced
after co-culturing with either LPS or ApoAct after
normalization to two different reference genes. Real-time
PCR was used to determine fold changes in mRNA for
APOBEC3G in DCs co-cultured with LPS, resting apoptotic
allogeneic CD4
+ T cells (ApoRest), or activated apoptotic
allogeneic CD4
+ T cells (ApoAct). Cycle threshold values for
APOBEC3G were normalized either to the value for GAPDH or
18s RNA. mRNA levels were compared with DCs cultured in
medium for 24 hours. Data represent the mean 6 SD from four
different donors.
(EPS)
Figure S6 Efficiency of APOBEC3G silencing in DCs by
siRNA. (A) To silence APOBEC3G, the DCs were either
transfected with APOBEC3G specific siRNA (siA3G), Non-
Targeting siRNA (siNonTarget) or not exposed to the transfection
procedure. Real-time PCR was used to determine the efficiency of
the silencing by measuring the fold changes in mRNA for
APOBEC3G in DCs co-cultured with LPS, resting apoptotic
allogeneic CD4
+ T cells (ApoRest), or activated apoptotic allogeneic
CD4
+T cells(ApoAct).The mRNA levelswerecomparedwith DCs
cultured in medium for 24 hours. Results are representative of two
donors. (B) Supernatant from DCs co-cultured with LPS, ApoRest,
or ApoAct that were either transfected with siA3G, siNonTarget or
not exposed to the transfection procedure, were collected after
24 hours and analyzed for the presence of TNF-a by performing an
ELISA. Results are representative of two donors.
(EPS)
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